Frontlight ResearchEarly access
Active, not recruitingPhase 1
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Ann Arbor, Baltimore, Dallas, Detroit, Farmington Hills, Houston, Iowa City, La Jolla, New York, Omaha, Philadelphia, Sacramento, and Salt Lake City, United StatesSee the 14 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 11 people enrolled
- Started
- 8 May 2017
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional
- Treatments tested
- Laboratory Biomarker Analysis
- Pharmacological Study
- Quality-of-Life Assessment
- Ropidoxuridine
- Whole-Brain Radiotherapy
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Patients must have histologically confirmed malignancy with brain metastases and are being recommended palliative WBRT
- Life expectancy of greater than 2 months to allow completion of study treatment and assessment of dose-limiting toxicity
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count >= 1,000/mcL
- Platelets >= 100,000/mcL
- Calculated creatinine clearance >= 45 mL/min/1.73 m\^2
- Total bilirubin:; If no known liver metastases: total bilirubin < 1.5 x institutional upper limit of normal (ULN); If known liver metastases, then: total bilirubin < 2.5 x ULN
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]):; If no known liver metastases: AST/SGOT and ALT/SGPT both < 2 x ULN; If known liver metastases, then: AST/SGOT and ALT/SGPT both < 5 x ULN
- Human immunodeficiency virus (HIV) positive (+) patients with CD4 counts >= 250 cells/mm\^3 on anti-viral therapy are eligible for the study
- Negative urine or serum pregnancy test result for females of child bearing potential only; Note: The effects of IPdR on the developing human fetus are unknown; for this reason and because radiation therapy is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of IPdR administration
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Presence of diffuse lepto or pachy meningeal carcinomatosis (focal/localized involvement from limited meningeal based metastases acceptable), greater than 1 cm mid-line shift, uncal herniation, or severe hemorrhage/hydrocephalous (small intra-lesional hemorrhage or anticipated surgical cavity is acceptable); patients with seizure at presentation who have been started on levetiracetam and have been stable for 48 hours prior to study registration are eligible at the discretion of treating physician
- Patients who have received systemic cytotoxic chemotherapy or approved oral targeted therapy or immunotherapy for 2 weeks, or other investigational agents for 3 weeks (4 half-lives for any oral targeted agents), or radiotherapy to a non-brain site for 2 weeks before initiation of IPdR therapy; patients who have recovered from serious (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or more higher) to grade 1 or less adverse events from the previous therapies are eligible; prior/current/future hormonal therapy and/or bisphosphonates are permitted with no minimum interval to initiation of study therapy; if indicated, patients can receive palliative radiation therapy to a non-brain site concurrent or immediately post-study treatment with no minimum interval to initiation of study therapy
- Patients must not have received prior whole brain radiation therapy; previous SRS/SRT done at least 3 weeks from the planned start of IPdR therapy is acceptable; SRS/SRT/fractionated boosts or neurosurgery can be performed once the dose limiting toxicity (DLT) assessment has been completed, if felt clinically necessary
- Patients who are receiving any other investigational agent
- Patients needing more than 8 mg dexamethasone per day at the time of start of WBRT will not be eligible to participate in the study; however, patients will be allowed entry into the study if it is medically safe to reduce the daily dose of dexamethasone to 8 mg or less from the day of the start of WBRT; the dexamethasone dose for such patients may be increased beyond 8 mg per day during the course of treatment if medically necessary; this increased need for dose should be communicated to the study's principal investigator, Dr Mohindra at the University of Maryland
- Pregnant women are excluded from this study because IPdR is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with IPdR, breastfeeding should be discontinued if the mother is treated with IPdR
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
- Uncontrolled intercurrent illness if it would increase the risk of toxicity or limit compliance with study requirements; this includes, but is not limited to, ongoing uncontrolled serious infection requiring intravenous (i.v.) antibiotics, progressive congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with primary tumors including germ cell tumor, or lymphoma/leukemia
Where in United States
- University of Michigan Rogel Cancer CenterAnn Arbor, United States
- University of Maryland/Greenebaum Cancer CenterBaltimore, United States
- UT Southwestern/Simmons Cancer Center-DallasDallas, United States
- Wayne State University/Karmanos Cancer InstituteDetroit, United States
- Weisberg Cancer Treatment CenterFarmington Hills, United States
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston, United States
- Ben Taub General HospitalHouston, United States
- University of Iowa/Holden Comprehensive Cancer CenterIowa City, United States
- UC San Diego Moores Cancer CenterLa Jolla, United States
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, United States
- University of Nebraska Medical CenterOmaha, United States
- Fox Chase Cancer CenterPhiladelphia, United States
- University of California Davis Comprehensive Cancer CenterSacramento, United States
- Huntsman Cancer Institute/University of UtahSalt Lake City, United States
About the trial
What the trial wants to find out
This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cells more sensitive to the radiation therapy.
The group in the trial
- Treatment (ropidoxuridine, WBRT)Treatment being tested
Patients receive ropidoxuridine PO QD on days 1-28 and undergo WBRT daily for not more than 5 days per week beginning on day 8 for a total of 15 fractions in the absence of disease progression or unacceptable toxicity.
Treatment: Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Ropidoxuridine, and Whole-Brain Radiotherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
- Record updated
- 13 November 2026